Clinical and Genetic Risk Factors of Long-Term Outcomes after Encephaloduroarteriosynangiosis in Moyamoya Disease in China
- PMID: 33992965
- DOI: 10.1016/j.jstrokecerebrovasdis.2021.105847
Clinical and Genetic Risk Factors of Long-Term Outcomes after Encephaloduroarteriosynangiosis in Moyamoya Disease in China
Abstract
Objectives: This retrospective study was conducted to analyze the associations between ring finger protein 213 p.R4810K variant, clinical features and long-term outcomes in patients with moyamoya disease (MMD) after encephaloduroarteriosynangiosis treatment.
Materials and methods: A total of 2,545 patients with MMD in China were included in this study (median of follow-up duration: 32.00 months). Multiple Cox regression models were used to assess the associations between p.R4810K variant, clinical features and long-term outcomes.
Results: For all patients, in multivariate Cox analysis, no association was observed between p.R4810K and long-term outcomes. Pediatric onset (HR, 0.38; 95%CI, 0.25-0.59) and headache (HR, 0.26; 95%CI, 0.08-0.83) were inversely and hypertension (HR, 1.43 95%CI, 1.06-1.94), diabetes (HR, 1.55; 95%CI, 1.00-2.40), bilateral lesions (HR, 2.73; 95%CI, 1.12-6.65) and posterior cerebral artery involvement (HR, 1.44; 95%CI, 1.08-1.90) were positively associated with follow-up stroke (all P < 0.05). Pediatric onset (HR, 0.46; 95%CI, 0.26-0.82) was inversely and hyperlipidemia (HR, 1.83; 95%CI, 1.23-2.73), smoking (HR, 1.86; 95%CI, 1.13-3.07), high Suzuki angiographic stage (HR, 1.71, 95%CI, 1.09-2.70), poor admission neurologic status (HR, 8.93; 95%CI, 6.49-12.29) and follow-up stroke (HR, 8.31; 95%CI, 6.01-11.49) were positively associated with poor neurologic outcome at the last follow-up visit (all P < 0.05). The factors were not consistent in the different groups of age at onset.
Conclusions: In our study, p.R4810K may play no role in long-term outcomes in Chinese MMD. Clinical features including age at onset, initial symptoms, risk factors of stroke, imaging, poor admission neurologic status were associated with poor outcomes in MMD after EDAS.
Keywords: encephaloduroarteriosynangiosis; moyamoya disease; outcome; ring finger protein 213; stroke.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no competing interests to declare.
Similar articles
-
The Association of Heterozygous p.R4810K of RNF213 and Long-Term Unfavorable Outcomes after Encephaloduroarteriosynangiosis in Chinese Pediatric Patients with Moyamoya Disease.Hum Mutat. 2024 Apr 24;2024:1844190. doi: 10.1155/2024/1844190. eCollection 2024. Hum Mutat. 2024. PMID: 40225941 Free PMC article.
-
Association between p.R4810K Variant and Postoperative Collateral Formation in Patients with Moyamoya Disease.Cerebrovasc Dis. 2019;48(1-2):77-84. doi: 10.1159/000503250. Epub 2019 Oct 2. Cerebrovasc Dis. 2019. PMID: 31578010
-
Genotype-Phenotype Correlation in Long-Term Cohort of Japanese Patients with Moyamoya Disease.Cerebrovasc Dis. 2019;47(3-4):105-111. doi: 10.1159/000499699. Epub 2019 Apr 4. Cerebrovasc Dis. 2019. PMID: 30947170
-
Clinical Features and Surgical Outcomes of Patients With Moyamoya Disease and the Homozygous RNF213 p.R4810K Variant.J Child Neurol. 2019 Nov;34(13):793-800. doi: 10.1177/0883073819858264. Epub 2019 Jul 10. J Child Neurol. 2019. PMID: 31290353 Review.
-
The Association of the RNF213 p.R4810K Polymorphism with Quasi-Moyamoya Disease and a Review of the Pertinent Literature.World Neurosurg. 2017 Mar;99:701-708.e1. doi: 10.1016/j.wneu.2016.12.119. Epub 2017 Jan 5. World Neurosurg. 2017. PMID: 28063898 Review.
Cited by
-
The impact of hypertension on clinical outcomes in moyamoya disease: a multicenter, propensity score-matched analysis.Acta Neurochir (Wien). 2024 Sep 13;166(1):366. doi: 10.1007/s00701-024-06254-0. Acta Neurochir (Wien). 2024. PMID: 39269654 Free PMC article.
-
RNF213 in moyamoya disease: Genotype-phenotype association and the underlying mechanism.Chin Med J (Engl). 2024 Nov 5;137(21):2552-2560. doi: 10.1097/CM9.0000000000002985. Epub 2024 Jan 19. Chin Med J (Engl). 2024. PMID: 38243713 Free PMC article. Review.
-
Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions.MedComm (2020). 2025 Jan 14;6(2):e70054. doi: 10.1002/mco2.70054. eCollection 2025 Feb. MedComm (2020). 2025. PMID: 39822761 Free PMC article. Review.
-
Impact of Revascularization Timing on Clinical Outcomes of Symptomatic Moyamoya Disease: A Systematic Review and Multivariate Analysis.Neurosurg Pract. 2025 Jan 7;6(1):e00126. doi: 10.1227/neuprac.0000000000000126. eCollection 2025 Mar. Neurosurg Pract. 2025. PMID: 39958483 Free PMC article. Review.
-
The Association of Heterozygous p.R4810K of RNF213 and Long-Term Unfavorable Outcomes after Encephaloduroarteriosynangiosis in Chinese Pediatric Patients with Moyamoya Disease.Hum Mutat. 2024 Apr 24;2024:1844190. doi: 10.1155/2024/1844190. eCollection 2024. Hum Mutat. 2024. PMID: 40225941 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical